Designing a FGF1-FGF21 chimeric protein with enhanced activities
by Phan, P.; Okoto, P.; Thallapuranam, S.
The fibroblast growth factor (FGF) family is consisted of 22 proteins that mediates various biological functions: from wound healing, tissue repairs, to angiogenesis and glucose regulations. There are three main modes of action within FGFs: paracrine, intracrine or endocrine. FGF1 is one of the paracrine FGFs that works locally through interaction with FGF receptors and heparin sulfate (HS) to regulate developmental processes: cell growth and differentiation, tissue repairs, and tumor growth and invasion. The FGF1 has been studied extensively and led to the construction of a variant termed SuperFGF1. SuperFGF1 exhibits increased thermal, chemical, and proteolytic stability, enhanced bioactivity, and reduced HS binding affinity. FGF21 is an endocrine FGFs that participates in long range physiological processes but does not require HS. It engages in a plethora of regulations across various organs. The most notable activity of FGF21 is its mediation of glucose uptake in adipocytes. Thus, FGF21 is an attractive therapeutic agent for metabolic diseases such as Type-2 Diabetes. However, FGF21 possesses an inherently unstable core with low thermal stability and receptor affinity. Herein, we designed a structure-based chimera protein by fusing the physiologically active FGF21 C-terminal with a thermally stable FGF1 variant. Using circular dichroism spectroscopy, we show that the chimera protein sFGF1-FGF21 adopts a a-helix motif. Intrinsic fluorescence spectra of the chimera protein shows an emission maximum centered at 345 nm indicating that the emission of the conserved tryptophan is not quenched, similar to wildtype FGF21. Differential calorimetry data suggest that chimera sFGF1-FGF21 is significantly more stable than wild type FGF21. Trypsin digestion assay indicates that the chimera is prone to proteolytic cleavage, similar to FGF21. Cell proliferation assay with NIH3T3 showed that the chimera protein has strong proliferative activity. The findings of this study provide valuable clues for the rational design of FGF21-based therapeutic against metabolic diseases.